Francesca Puggioni, MD

Experts at ERS Congress 2026 discuss why attending respiratory conferences drives learning, networking, and better patient outcomes.

Francesca Puggioni, MD, explains how real-world registry data, like the EU-ADVANTAGE study, informs regulatory decisions on asthma biologics.

Francesca Puggioni, MD, discusses real-world exacerbations, biomarker-driven access, and barriers to earlier biologic use in asthma and COPD.

Francesca Puggioni, MD, explains how multidisciplinary teams choose COPD biologics and why systemic inflammation matters as much as FEV1.